Phototherapy with artificial light suppresses dextran sulfate sodium-induced colitis in a mouse model
Takahiro Hiratsuka
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorCorresponding Author
Masafumi Inomata
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan
Correspondence
Dr Masafumi Inomata, Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, 1-1 Idaigaoka, Yufu, Oita 879-5593, Japan. Email: [email protected]
Search for more papers by this authorShigeru Goto
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
Search for more papers by this authorYoshimasa Oyama
Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorToshiaki Nakano
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
Search for more papers by this authorChao-Long Chen
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
Search for more papers by this authorNorio Shiraishi
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorTakayuki Noguchi
Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorTakahiro Hiratsuka
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorCorresponding Author
Masafumi Inomata
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan
Correspondence
Dr Masafumi Inomata, Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, 1-1 Idaigaoka, Yufu, Oita 879-5593, Japan. Email: [email protected]
Search for more papers by this authorShigeru Goto
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
Search for more papers by this authorYoshimasa Oyama
Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorToshiaki Nakano
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
Search for more papers by this authorChao-Long Chen
Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
Search for more papers by this authorNorio Shiraishi
Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorTakayuki Noguchi
Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, Oita, Japan
Search for more papers by this authorAbstract
Background and Aim
Medical treatment for inflammatory bowel disease (IBD) requires chronic administration and causes side effects. Recently, anti-inflammatory effects of phototherapy were reported in animal models. The present study evaluated whether phototherapy improves dextran sulfate sodium (DSS)-induced colitis in a mouse model of IBD.
Methods
Mice were divided into four equal groups: Control, DSS, DSS + light low (LL), and DSS + light high (LH) groups. Normal fluorescent light intensity in the Control and DSS groups was 200 lux. Artificial light intensities were as follows: DSS + LL group, 1000 lux; DSS + LH group, 2500 lux. After administering phototherapy for 7 days, we evaluated disease activity index (DAI), histological score, colon length/weight, serum 1,25-dihydroxyvitamin D(3) level, and serum and colonic cytokines in the mice.
Results
DAI and histological scores were significantly lower in the DSS + LL group than in the DSS group (both, P < 0.05). Colon length and weight were significantly higher in the DSS + LL group than in the DSS group (both, P < 0.05). Serum interleukin (IL)-6, TNF-α, and IL-17 in the DSS + LL group were significantly lower, and serum and colonic IL-10 were significantly higher in the DSS + LL group than in the DSS group (all, P < 0.05). Serum 1,25-dihydroxyvitamin D(3) levels in the DSS + LH group were significantly increased compared with those in the DSS + LL and DSS groups.
Conclusion
Artificial light phototherapy suppressed DSS-induced colitis in mice by suppression of pro-inflammatory cytokines and promotion of anti-inflammatory cytokines.
Supporting Information
| Filename | Description |
|---|---|
| jgh12460-sup-0001-si.pptx569 KB |
Figure S1 Experimental environment. Figure S2 Photographs of the colon of each group on day 14. DSS, dextran sulfate sodium; LH, light high; LL, light low. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J. Gastroenterol. Hepatol. 2012; 27: 1266–1280.
- 2 Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54 e42; quiz e30.
- 3 Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med. 2002; 347: 417–429.
- 4 Jones DT, Osterman MT, Bewtra M, Lewis JD. Passive smoking and inflammatory bowel disease: a meta-analysis. Am. J. Gastroenterol. 2008; 103: 2382–2393.
- 5 Teshima C, Fedorak RN. Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment? Inflamm. Bowel Dis. 2008; 14 (Suppl. 2): S216–218.
- 6 Munavalli GS, Weiss RA. Evidence for laser- and light-based treatment of acne vulgaris. Semin. Cutan. Med. Surg. 2008; 27: 207–211.
- 7 Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N. Engl. J. Med. 2008; 358: 920–928.
- 8 Mafra de Lima F, Naves KT, Machado AH, Albertini R, Villaverde AB, Aimbire F. Lung inflammation and endothelial cell damage are decreased after treatment with phototherapy (PhT) in a model of acute lung injury induced by Escherichia coli lipopolysaccharide in the rat. Cell Biol. Int. 2009; 33: 1212–1221.
- 9 Nakano T, Cheng YF, Lai CY et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J. Hepatol. 2011; 55: 415–425.
- 10 Muili KA, Gopalakrishnan S, Meyer SL, Eells JT, Lyons JA. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by photobiomodulation induced by 670 nm light. PLoS ONE 2012; 7: e30655.
- 11 Halliday GM, Damian DL, Rana S, Byrne SN. The suppressive effects of ultraviolet radiation on immunity in the skin and internal organs: implications for autoimmunity. J. Dermatol. Sci. 2012; 66: 176–182.
- 12 Nerich V, Jantchou P, Boutron-Ruault MC et al. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment. Pharmacol. Ther. 2011; 33: 940–945.
- 13 Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993; 69: 238–249.
- 14 Youn J, Lee JS, Na HK, Kundu JK, Surh YJ. Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. Nutr. Cancer 2009; 61: 847–854.
- 15 Hiratsuka T, Inomata M, Hagiwara S et al. Bolus injection of newly synthesized vitamin E derivative ETS-GS for the treatment of acute severe ulcerative colitis in a mouse model: new vitamin E derivative for acute severe UC. Int. J. Colorectal Dis. 2013; 28: 305–311.
- 16 Alex P, Zachos NC, Nguyen T et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 2009; 15: 341–352.
- 17 Marshall JS, Leal-Berumen I, Nielsen L, Glibetic M, Jordana M. Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J. Clin. Invest. 1996; 97: 1122–1128.
- 18 Heo YJ, Joo YB, Oh HJ et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol. Lett. 2010; 127: 150–156.
- 19 Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J. Gastroenterol. 2008; 14: 5154–5161.
- 20 Marlow GJ, van Gent D, Ferguson LR. Why interleukin-10 supplementation does not work in Crohn's disease patients. World J. Gastroenterol. 2013; 19: 3931–3941.
- 21 Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 1434–1444.
- 22 Correa I, Veny M, Esteller M et al. Defective IL-10 production in severe phenotypes of Crohn's disease. J. Leukoc. Biol. 2009; 85: 896–903.
- 23 Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010; 10: 170–181.
- 24 Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J. Immunol. 2008; 180: 2752–2756.
- 25 Kanai T, Watanabe M. Clinical application of human CD4+ CD25+ regulatory T cells for the treatment of inflammatory bowel diseases. Expert Opin. Biol. Ther. 2005; 5: 451–462.
- 26 Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology 2012; 136: 115–122.
- 27 Murai M, Turovskaya O, Kim G et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 2009; 10: 1178–1184.
- 28 Jorgensen SP, Agnholt J, Glerup H et al. Clinical trial: vitamin D3 treatment in Crohn's disease—a randomized double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 2010; 32: 377–383.
- 29 Miheller P, Muzes G, Hritz I et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm. Bowel Dis. 2009; 15: 1656–1662.
- 30 Cantorna MT. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch. Biochem. Biophys. 2012; 523: 103–106.
- 31 Ryz NR, Patterson SJ, Zhang Y et al. Active vitamin D (1,25-dihydroxyvitamin D3) increases host susceptibility to Citrobacter rodentium by suppressing mucosal Th17 responses. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 303: G1299–1311.
- 32 Wang Y, Marling SJ, McKnight SM, Danielson AL, Severson KS, Deluca HF. Suppression of experimental autoimmune encephalomyelitis by 300–315nm ultraviolet light. Arch. Biochem. Biophys. 2013; 536: 81–86.
- 33 Koltun WA. Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev. Gastroenterol. Hepatol. 2009; 3: 325–327.
- 34 Colin EM, Asmawidjaja PS, van Hamburg JP et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 2010; 62: 132–142.
- 35 Tang J, Zhou R, Luger D et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J. Immunol. 2009; 182: 4624–4632.
- 36 Chen M, Mei Q, Xu J, Lu C, Fang H, Liu X. Detection of melatonin and homocysteine simultaneously in ulcerative colitis. Clin. Chim. Acta 2012; 413: 30–33.
- 37 Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr. Pharm. Des. 2011; 17: 4372–4378.
- 38 Cuzzocrea S, Mazzon E, Serraino I et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J. Pineal Res. 2001; 30: 1–12.
- 39 Kozaki T, Toda N, Noguchi H, Yasukouchi A. Effects of different light intensities in the morning on dim light melatonin onset. J. Physiol. Anthropol. 2011; 30: 97–102.
- 40 Motomura Y, Kitamura H, Hijikata A et al. The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat. Immunol. 2011; 12: 450–459.
Citing Literature
